期刊
JOURNAL OF BONE AND MINERAL RESEARCH
卷 34, 期 10, 页码 1780-1788出版社
WILEY
DOI: 10.1002/jbmr.3852
关键词
CANCER; OSTEOIMMUNOLOGY; OTHER; PRIMARY TUMORS OF BONE AND CARTILAGE; SYSTEMS BIOLOGY - BONE INTERACTORS; THERAPEUTICS
资金
- NCI NIH HHS [R21 CA205794] Funding Source: Medline
Primary malignant bone tumors are rare, occur in all age groups, and include distinct entities such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. Traditional treatment with some combination of chemotherapy, surgery, and radiation has reached the limit of efficacy, with substantial room for improvement in patient outcome. Furthermore, genomic characterization of these tumors reveals a paucity of actionable molecular targets. Against this backdrop, recent advances in cancer immunotherapy represent a silver lining in the treatment of primary bone cancer. Major strategies in cancer immunotherapy include stimulating naturally occurring anti-tumor T cells and adoptive transfer of tumor-specific cytotoxic T cells. Chimeric antigen receptor T cells (CAR-T cells) belong to the latter strategy and are an impressive application of both insights into T cell biology and advances in genetic engineering. In this review, we briefly describe the CAR-T approach and discuss its applications in primary bone tumors. (c) 2019 American Society for Bone and Mineral Research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据